Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALLO 2.89 +0.04(1.23%)
Will ALLO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Allogene (ALLO) Stock Stands Out in a Strong Industry
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Other News for ALLO
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Allogene Therapeutics At $2.50, Earn 32.6% Annualized Using Options
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene awarded $15M grant from CIRM to support ALLO-316 development
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation